Cadence Solutions, Inc. Startup Diligence Research Report
Upside is a health-system embedded chronic-care infrastructure platform with validated outcomes and APCM/RPM reimbursement tailwinds; downside is labor-intensive services revenue with high compliance exposure and opaque economics.
Cadence Solutions, Inc. Startup Diligence Research Report
Cadence shows credible public traction in AI-enabled remote chronic care, but financial, customer, reimbursement, clinical-safety, and regulatory diligence remain essential before relying on the $1B+ valuation.
Financing and valuation references are public, but financial statements, ARR, margin, cash, and runway are private.
Diligence request: Request audited financials, KPIs, budget-to-actuals, bank/debt records, board decks, and valuation support.
RPM/CCM/APCM/telehealth services depend on Medicare/payer billing, consent, supervision, coding, and audit compliance.
Diligence request: Review billing policies, legal opinions, payer contracts, coding audits, denial rates, and compliance minutes.
Positive outcomes claims need full methods, conflicts, raw claims, adverse-event, and customer-specific validation.
Diligence request: Have clinical/statistical experts review full studies, data, adverse events, and partner outcomes.
Named health systems are strong signals, but revenue concentration, active lives, renewals, and churn are private.
Diligence request: Request customer revenue schedule, active lives, renewal/churn, backlog, implementation dashboards, and reference calls.
Cadence handles PHI, uses AI workflows/voice technology, and operates a security program; independent certifications were not public.
Diligence request: Review HIPAA risk analysis, SOC 2/HITRUST, BAAs, breach logs, AI governance, pen tests, and vendor risk.
Care model depends on licensed clinical staff, remote roles, state licensure, supervision, and retention.
Diligence request: Request licensure matrix, staffing ratios, credentialing, malpractice coverage, turnover, and QA audits.
Public sources identify 2021 financings but not current ownership, preferences, debt, option pool, cash, or runway.
Diligence request: Request fully diluted cap table, investor rights, debt/notes, option plan, 409A, and financing plan.
RPM, virtual chronic care, and care-at-home markets have multiple scaled competitors and adjacent platforms.
Diligence request: Run win/loss interviews, pricing benchmark, buyer survey, and competitor product comparison.
Public evidence verifies identity, 2021 financings, and reported $1B valuation; operating financial quality remains private.
not publicly verifiable confidence: high
Annual and quarterly financial information for the past three years: public evidence and diligence gaps are documented in linked claims and exhibits.
| metric | public signal | status | risk | diligence request |
|---|---|---|---|---|
| Revenue / ARR | SEC revenue range declined to disclose; no ARR public | not_publicly_verifiable | No valuation bridge | Audited financials, ARR, revenue by customer/product. |
| Scale | 20+ or 21 health systems and >90,000 patients claimed | partially_verified | Scale may not equal recurring revenue | Active/revenue-generating lives and ARR by customer. |
| Gross margin | Clinical care team and licensed roles are visible; margin not public | not_publicly_verifiable | Services labor may limit software margins | COGS by labor, devices, support, cloud, claims admin. |
| Cash / burn / runway | No public records found | not_publicly_verifiable | Financing need unknown | Bank, payables, debt, budget, runway plan. |
Stub rows are included where private financials are unavailable.
partially verified confidence: medium
Financial Projections: public evidence and diligence gaps are documented in linked claims and exhibits.
partially verified confidence: medium
Capital Structure: public evidence and diligence gaps are documented in linked claims and exhibits.
| stakeholder | public position | evidence | status | diligence request |
|---|---|---|---|---|
| Chris Altchek | CEO, founder, executive officer/director, signer | Launch post, SEC filings, unicorn list | verified | Equity, vesting, employment agreement, board status. |
| Kareem Zaki / Thrive | Co-founder and director signal | Launch post and Form D related person | verified | Ownership and board/investor rights. |
| General Catalyst / Hemant Taneja | Lead investor and director signal | Launch post and Form D related person | verified | Investor rights and side letters. |
| Coatue | Series B lead reported by trade press | pharmaphorum article | partially_verified | Confirm securities and governance rights. |
| Other holders / options / debt | not public | No cap table, debt, or option plan public | not_publicly_verifiable | Fully diluted cap table, debt, warrants, option pool. |
Ownership percentages are not public.
partially verified confidence: medium
Other financial information: public evidence and diligence gaps are documented in linked claims and exhibits.
| date | event | amount | valuation | status | diligence request |
|---|---|---|---|---|---|
| 2021-06-29 / 2021-07-14 | Launch / Series A Form D | $40,911,524 sold; $41M launch funding | not disclosed | verified | Series A documents, price per share, cap table. |
| 2021-12-07 / 2021-12-15 | Series B Form D / trade press round | $102,549,999 sold; trade press says $100M | $1B reported by list/trade press | partially_verified | Closing schedule, preferences, side letters. |
| 2022-2026 | Later financings | not public in fetched EDGAR feed | not publicly verifiable | not_publicly_verifiable | All equity/debt/SAFE/note/secondary transactions. |
Form D does not disclose valuation or full cap table.
Public product evidence is strong, but architecture, AI validation, economics, and safety require data-room review.
partially verified confidence: medium
Description of each product: public evidence and diligence gaps are documented in linked claims and exhibits.
| product | audience | features | conditions | status | diligence request |
|---|---|---|---|---|---|
| Clinical Intelligence / Remote Patient Care | health systems, clinicians, older adults | vitals/symptoms/medications/engagement tracking; AI agents; care team | hypertension, heart failure, diabetes, COPD | verified | Demo, architecture, model validation, protocols. |
| Care in Sync legacy platform | partner clinicians and patients | collects vitals, medical history, wellness data; machine learning | heart failure, COPD, type 2 diabetes, hypertension | verified | Roadmap/migration from Care in Sync to Clinical Intelligence. |
| RPM / CCM / APCM / telehealth services | Medicare and covered patients through providers | remote monitoring, chronic care management, advanced primary care management | chronic condition populations | verified | Billing workflow, compliance, claims denials. |
| Outcomes evidence layer | buyers, payers, clinicians | Mayo/JACC/AHA summaries on cost, admissions, BP, GDMT | hypertension and heart failure emphasized | partially_verified | Full papers, raw claims, adverse events, statistician review. |
SKU economics are private.
| element | public evidence | implication | status | diligence request |
|---|---|---|---|---|
| Commercial pricing | No public enterprise price schedule found | ARR/margin cannot be public-validated | not_publicly_verifiable | MSAs, order forms, value-based terms. |
| Patient cost-sharing | Terms disclose copays, coinsurance, deductibles, separate payments | Can affect engagement and complaints | verified | Billing scripts, collections, complaints. |
| APCM reimbursement | CMS finalized G0556/G0557/G0558 | Potential tailwind; compliance risk | verified | Coding policies, payer contracts, denial rates. |
| Outcome-based economics | Cost/hospitalization reduction claims in studies | Value-based upside needs validation | partially_verified | Attribution, claims data, risk-sharing contracts. |
Public pricing is a major gap.
Inferred, not engineering documentation.
Multiple health-system partnerships are public; revenue concentration, active deployments, churn, and supplier spend are private.
partially verified confidence: medium
Top customers by application: public evidence and diligence gaps are documented in linked claims and exhibits.
| customer | use case | public scale | status | diligence request |
|---|---|---|---|---|
| LifePoint Health | founding remote care partnership | over 100,000 people at full rollout claimed | partially_verified | Active status, revenue, renewal, reference. |
| Community Health Systems | RPM/virtual care for chronic conditions | thousands of patients claimed | verified | Contract, active lives, revenue. |
| Providence | RPM in Washington; broader seven-state focus | over 300 active patients; 89% daily vitals at disclosure | partially_verified | Current expansion and outcomes. |
| Ardent | RPM/responsive virtual care | 30 hospitals, 200 sites in six states | verified | Market-by-market rollout and economics. |
| RUSH / Memorial Hermann | Medicare/Medicaid chronic monitoring; RPM/APCM | patient counts not disclosed in announcements | verified | Go-live, active lives, pricing, references. |
Customer revenue/concentration is private.
partially verified confidence: medium
Strategic relationships: public evidence and diligence gaps are documented in linked claims and exhibits.
| partner | relationship | strategic value | public evidence | gap |
|---|---|---|---|---|
| LifePoint | founding health-system partner | early community/rural validation | launch post | current status and revenue |
| Providence | health-system partner; source of CMO background | large system and virtual-care expertise | Providence announcement and CMO post | customer concentration and independence |
| General Catalyst / Thrive / Coatue | investors / governance ecosystem | capital and healthcare networks | launch, SEC, trade press | rights, reserves, pro rata |
| Newer systems | expansion customers | supports 20+ system scale claim | homepage and Memorial Hermann post | contracted vs live status |
Economics and obligations are private.
not publicly verifiable confidence: high
Revenue by customer: public evidence and diligence gaps are documented in linked claims and exhibits.
partially verified confidence: medium
Significant relationships severed within the last two years: public evidence and diligence gaps are documented in linked claims and exhibits.
partially verified confidence: medium
Top suppliers: public evidence and diligence gaps are documented in linked claims and exhibits.
| dependency | role | public evidence | risk | diligence request |
|---|---|---|---|---|
| Connected devices | capture vitals | Terms list BP monitors, glucometers, scales, pulse oximeters; Cadence does not manufacture devices | quality, recalls, availability, data accuracy | vendor contracts, FDA clearances, recalls |
| EMR/HIE integrations | care coordination and data access | NPP mentions HIE; company bio says deep EMR integration | privacy, uptime, deployment complexity | BAAs, integration list, SLAs, uptime |
| Clinical workforce | monitoring, triage, interventions | Clinician page and open roles show licensed staff | licensure, retention, quality | licensure matrix, staffing ratios |
| AI/voice and analytics vendors | call routing and risk surfacing | privacy/NPP disclose AI voice; homepage claims AI agents | model safety, vendor, privacy | model/vendor list, BAAs, validation |
Spend and vendor concentration are private.
Market need is strong and competition is crowded; public data is insufficient for pricing power or share.
partially verified confidence: medium
Competitive landscape by market segment: public evidence and diligence gaps are documented in linked claims and exhibits.
| company | segment | scale signal | overlap | differentiator or risk |
|---|---|---|---|---|
| Cadence | AI-enabled chronic remote care for health systems | $1B reported valuation; 20+ systems/>90k patients claimed | RPM/CCM/APCM, clinical team | embedded health-system clinical model; economics private |
| Current Health | complex/high-acuity care at home | public positioning reviewed | AI-enabled remote management | high-acuity/advanced therapy emphasis |
| Biofourmis | AI-driven in-home care / RPM | 50+ health systems/payers claimed | remote patient management | global/pharma/care-continuum breadth |
| HRS | enterprise RPM/CCM | decade+ enterprise positioning and logos | direct RPM/CCM platform/services | mature category competitor |
| Omada | virtual chronic programs | programs for diabetes, hypertension, MSK | chronic outcomes budgets | employer/plan orientation |
Competitor funding not invented when not fetched.
| axis | cadence position | competitor position | evidence | gap |
|---|---|---|---|---|
| Outcomes evidence | multiple positive public study summaries | competitors also claim outcomes | EC-015 EC-016 EC-017 EC-029 | independent validation |
| Enterprise health-system sales | multiple named partnerships | Biofourmis/HRS also claim enterprise reach | EC-010 to EC-014 EC-029 | win/loss and pricing |
| AI plus clinical care team | Clinical Intelligence and care team | Current/Biofourmis AI-enabled care at home | EC-008 EC-029 | model validation and labor leverage |
| Defensibility | registered mark; patent search inconclusive | unknown from this research | EC-024 EC-026 | IP/FTO landscape |
Qualitative public-evidence scoring only.
Coordinates are analyst qualitative scores.
GTM appears enterprise health-system-led with outcomes and reimbursement content; CAC, pipeline, and productivity are private.
partially verified confidence: medium
Strategy and implementation: public evidence and diligence gaps are documented in linked claims and exhibits.
| channel | target | public evidence | status | diligence request |
|---|---|---|---|---|
| Enterprise health-system partnerships | executives, clinical/value-based leaders | LifePoint, CHS, Ardent, Providence, RUSH, Memorial Hermann | verified | CRM, ACV, sales cycle, win rate |
| Clinician enablement | partner clinicians | workflow burden and escalation claims | partially_verified | clinician NPS and workflow metrics |
| Reimbursement-enabled services | Medicare populations and providers | APCM/RPM terms and CMS codes | verified | billing compliance and denial rates |
| Outcomes content marketing | health-system buyers/payers | Mayo/JACC/AHA summaries | partially_verified | lead attribution and CAC |
GTM economics are private.
| signal | observation | strength | risk | diligence request |
|---|---|---|---|---|
| Trade press | $1B valuation coverage | medium | valuation story may outpace metrics | investor memo and revenue bridge |
| Outcomes marketing | multiple company summaries of studies | medium | bias/attribution | full publications and data |
| Recruiting brand | LinkedIn Top Startups post and open roles | medium | not retention proof | headcount and turnover |
| Consumer app-store | no clear first-party app signal found | low | public product adoption opaque | app IDs and patient metrics |
Mostly company-owned signals.
Scores are analyst-coded, not disclosed channel mix.
partially verified confidence: medium
Major Customers: public evidence and diligence gaps are documented in linked claims and exhibits.
partially verified confidence: medium
Principal avenues for generating new business: public evidence and diligence gaps are documented in linked claims and exhibits.
not publicly verifiable confidence: high
Sales force productivity model: public evidence and diligence gaps are documented in linked claims and exhibits.
partially verified confidence: medium
Ability to implement marketing plan with current and projected budgets: public evidence and diligence gaps are documented in linked claims and exhibits.
R&D centers on Clinical Intelligence, clinical workflows, device/EMR integrations, APCM, and outcomes research; budget and roadmap are private.
partially verified confidence: medium
Description of R&D organization: public evidence and diligence gaps are documented in linked claims and exhibits.
| name or role | public role | background signal | source | diligence request |
|---|---|---|---|---|
| Chris Altchek | CEO & Founder | founder, Form D signer, public spokesperson | launch/SEC/leadership | succession and employment agreement |
| Dr. Eve Cunningham | CMO | Providence virtual care/digital health; AI clinical support | CMO post | clinical governance and credentialing |
| AI/data/engineering roles | Applied AI, Senior AI, data, DevOps, security | open roles show R&D/infrastructure hiring | open roles | R&D org, roadmap, security staffing |
| Founding technical/clinical team | CTO, CMO, product, care delivery, partnerships | launch post named multiple founding leaders | launch post | current tenure/departures |
Current reporting lines private.
partially verified confidence: medium
New Product Pipeline: public evidence and diligence gaps are documented in linked claims and exhibits.
| initiative | status public | evidence | status | diligence request |
|---|---|---|---|---|
| Clinical Intelligence / AI care | current marketed product | homepage and partner announcements | verified | model cards, validation, FDA analysis |
| APCM services expansion | publicly mentioned in 2026 partnership | Memorial Hermann plus CMS codes | partially_verified | go-live, claim volume, compliance review |
| Outcomes research | multiple 2025 study summaries | Mayo, AHA, JACC summaries | partially_verified | publication roadmap and raw data |
| Device/EMR/HIE integrations | implied by terms/NPP/bio | device list, HIE participation, EMR integration claim | partially_verified | integration roadmap and SLAs |
R&D budget and sprint roadmap not public.
Public sources identify founder/CEO and several leaders plus hiring signals; headcount, compensation, and turnover are private.
partially verified confidence: medium
Organization Chart: public evidence and diligence gaps are documented in linked claims and exhibits.
Reporting lines inferred; request actual org chart.
partially verified confidence: medium
Historical and projected headcount by function and location: public evidence and diligence gaps are documented in linked claims and exhibits.
| anchor | public signal | function mix | status | diligence request |
|---|---|---|---|---|
| 2021 trade press | expected 155 clinicians by mid-2022 | clinical care delivery | partially_verified | historical headcount and staffing plan |
| 2026 scale | 21 systems and >90,000 patients | company-wide scaling | partially_verified | current employee count by function |
| careers snapshot | clinical, AI, sales, legal, finance, IT roles | clinical and technology-heavy hiring | verified | open requisitions and offer pipeline |
| turnover/projection | not public | unknown | not_publicly_verifiable | HRIS, turnover, hiring plan, benefits |
Open roles are point-in-time.
partially verified confidence: medium
Senior management biographies: public evidence and diligence gaps are documented in linked claims and exhibits.
| name | role | public date | background | status | diligence request |
|---|---|---|---|---|---|
| Chris Altchek | CEO & Founder | founder at launch; CEO through 2026 posts | not independently researched beyond public company/SEC sources | verified | bio, references, comp, equity |
| Dr. Eve Cunningham | Chief Medical Officer | appointed 2025-02-25 | Providence virtual care/digital health; MedPearl | verified | employment agreement and clinical authority |
| Chris Holmes | Chief Financial Officer | effective February 23 per company post | Opendoor and Uber | partially_verified | finance controls and audit readiness |
| Casey Bailey | Chief People Officer | effective February 23 per company post | Deel, Divvy, Uber | partially_verified | people plan and retention metrics |
Limited to leaders surfaced publicly.
not publicly verifiable confidence: high
Compensation arrangements: public evidence and diligence gaps are documented in linked claims and exhibits.
not publicly verifiable confidence: high
Incentive stock plans: public evidence and diligence gaps are documented in linked claims and exhibits.
partially verified confidence: medium
Significant employee relations problems, past or present: public evidence and diligence gaps are documented in linked claims and exhibits.
partially verified confidence: medium
Personnel Turnover: public evidence and diligence gaps are documented in linked claims and exhibits.
Policies show HIPAA/privacy/security posture and registered trademark; comprehensive legal, regulatory, and IP diligence remains needed.
unverified confidence: medium
Pending lawsuits against the Company: public evidence and diligence gaps are documented in linked claims and exhibits.
| matter | public result | status | source | diligence request |
|---|---|---|---|---|
| Pending lawsuits against company | CourtListener exact opinion search returned zero results | unverified | CourtListener | PACER/state docket/arbitration search |
| Company-initiated lawsuits | No public case found in reviewed sources | not_publicly_verifiable | public search scope | legal claims schedule |
| Privacy/regulatory complaints | Policies disclose HIPAA/privacy obligations; no enforcement source found | not_publicly_verifiable | privacy/NPP | OCR/FTC/state/CMS searches and breach log |
| Patient billing/terms disputes | terms disclose financial responsibility and termination conditions | partially_verified | terms | complaints, refunds, collections |
No legal conclusion; search is not comprehensive.
partially verified confidence: medium
Pending lawsuits initiated by Company: public evidence and diligence gaps are documented in linked claims and exhibits.
partially verified confidence: medium
Environmental and employee safety issues and liabilities: public evidence and diligence gaps are documented in linked claims and exhibits.
partially verified confidence: medium
Material patents, copyrights, licenses, and trademarks: public evidence and diligence gaps are documented in linked claims and exhibits.
| area | public evidence | status | risk | diligence request |
|---|---|---|---|---|
| Trademark | CADENCE registered mark serial 97978759 / registration 7573821 | verified | brand protection but coexistence monitoring needed | TSDR verification and international marks |
| Patents | no visible Google Patents assignee results | inconclusive | limited public patent defensibility | patent/FTO/trade-secret review |
| Regulatory/privacy/security | HIPAA NPP, privacy policy, AI voice, HIE, vulnerability disclosure | verified | PHI/AI/cyber exposure | HIPAA risk analysis, SOC 2/HITRUST, BAAs, breach log |
| Material contracts / insurance | named partnerships and terms public; contracts/insurance not public | not_publicly_verifiable | unknown indemnities, SLAs, liability caps, coverage | MSAs, BAAs, insurance certificates, claims history |
Contracts and insurance remain private.
partially verified confidence: medium
Insurance coverage and material exposures: public evidence and diligence gaps are documented in linked claims and exhibits.
partially verified confidence: medium
Material contracts: public evidence and diligence gaps are documented in linked claims and exhibits.
partially verified confidence: medium
Regulatory agency problems: public evidence and diligence gaps are documented in linked claims and exhibits.
Risk points mirror risk_register.
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | Cadence Solutions, Inc. identity and Delaware corporation status are publicly verified. | verified high | SRC-003SRC-004SRC-005 |
| EC-002 | Cadence publicly launched with $41M funding led by General Catalyst and Thrive and named Chris Altchek and Kareem Zaki as founders. | verified high | SRC-002 |
| EC-003 | Cadence Series A Form D reported $40,911,524 sold to 24 investors. | verified high | SRC-004 |
| EC-004 | Cadence December 2021 Form D reported $102,549,999 sold on a $105,000,001 offering. | verified high | SRC-005 |
| EC-005 | Wikipedia unicorn list reports Cadence Solutions, Inc. at 1+ valuation in December 2021 with founder Chris Altchek. | partially verified medium | SRC-006 |
| EC-006 | Trade press reported a $1B valuation after a $100M financing led by Coatue. | partially verified medium | SRC-007 |
| EC-007 | Cadence currently brands itself as Clinical AI for Chronic Care trusted by 20+ health systems. | partially verified medium | SRC-001 |
| EC-008 | Cadence Clinical Intelligence tracks vitals, symptoms, medications, and engagement with AI-assisted care workflows. | verified medium | SRC-001 |
| EC-009 | Cadence publishes workflow and outcome claims including 0.2% escalation, 5.5x GDMT, and 50% cost reduction. | partially verified medium | SRC-008SRC-009 |
| EC-010 | CHS announced a Cadence partnership to deploy RPM and virtual care across its national footprint. | verified medium | SRC-010 |
| EC-011 | Providence partnership disclosed over 300 active patients, 89% daily vitals, and 0.2% escalation. | partially verified medium | SRC-011 |
| EC-012 | Ardent partnership covers 30 hospitals and 200 sites of care in six states. | verified medium | SRC-012 |
| EC-013 | RUSH launched a Cadence program for Medicare and Medicaid chronic-condition patients in Chicago. | verified medium | SRC-013 |
| EC-014 | Memorial Hermann announced AI-enabled RPM and APCM partnership; Cadence bio claims >90,000 patients and 20+ systems. | partially verified medium | SRC-014 |
| EC-015 | Company summary of Mayo Clinic Proceedings reports $1,302 lower annual cost and 27% fewer hospitalizations. | partially verified medium | SRC-015 |
| EC-016 | Cadence heart-failure analysis reported $183 monthly savings and 18% fewer admissions. | partially verified medium | SRC-016 |
| EC-017 | JACC Advances summary reports 23,638 hypertension patients, 7/5 mmHg BP drop, and 70% relative increase in BP-goal achievement. | partially verified medium | SRC-017 |
| EC-018 | Cadence announced CFO/CPO hires and reported 21 health systems and >90,000 patients. | partially verified medium | SRC-018 |
| EC-019 | Cadence appointed Dr. Eve Cunningham as Chief Medical Officer with Providence virtual-care and AI experience. | verified medium | SRC-019 |
| EC-020 | Cadence open roles show hiring across clinical, AI/software, partnerships, sales, legal, finance, people, and IT. | verified medium | SRC-020 |
| EC-021 | Cadence policy pages disclose health data, affiliated professional entities, HIPAA obligations, HIE participation, and AI voice technology. | verified medium | SRC-021SRC-022 |
| EC-022 | Cadence Terms define RPM, CCM, APCM, telehealth services, patient financial responsibility, and device dependencies. | verified medium | SRC-023 |
| EC-023 | Cadence maintains a vulnerability disclosure process with seven-business-day acknowledgement and ten-business-day critical triage. | verified medium | SRC-024 |
| EC-024 | Public trademark evidence reports CADENCE registered to Cadence Solutions, Inc. in classes 044, 042, and 010. | verified medium | SRC-025 |
| EC-025 | CourtListener exact search returned zero public opinion results for Cadence Solutions, Inc. | unverified medium | SRC-026 |
| EC-026 | Google Patents reader output did not surface visible patents assigned to Cadence Solutions, Inc. | inconclusive low | SRC-027 |
| EC-027 | CDC describes chronic disease as a leading driver of illness, death, and $4.9T annual U.S. healthcare cost. | verified high | SRC-028 |
| EC-028 | CMS finalized 2025 APCM payment codes G0556, G0557, and G0558. | verified high | SRC-029 |
| EC-029 | Current Health, Biofourmis, HRS, and Omada publicly position in overlapping remote care, RPM, in-home care, or chronic-care segments. | verified medium | SRC-030SRC-031SRC-032SRC-033 |
| EC-030 | Public app-store search did not reveal a clear first-party Cadence Solutions patient app signal. | inconclusive low | SRC-034 |
| EC-031 | Company recruiting materials say Cadence was named to LinkedIn Top Startups and show open roles. | partially verified medium | SRC-035SRC-020 |
| EC-032 | Revenue, ARR, gross margin, cash, burn, runway, debt, customer concentration, and cap table are not publicly verifiable. | not publicly verifiable high | SRC-003SRC-004SRC-005 |
| EC-033 | Fetched EDGAR company feed listed two Cadence Form D filings, both in 2021. | verified high | SRC-003 |
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.